Irvine drug maker Spectrum Pharmaceuticals Inc. said Thursday it signed a distribution deal and landed an investment from Par Pharmaceutical Cos. of New Jersey.
Spectrum is set to get $10 million in milestone payments from Woodcliff Lake, N.J.-based Par for each generic drug Spectrum successfully develops.
The companies are set to share profits from the sale of Spectrum’s generic drugs.
The deal also calls for Par to invest in Spectrum in the next two years.
Spectrum buys, develops and commercializes drugs mainly for treating cancer. Its lead prospect is Satraplatin, a cancer drug in third-phase trials.
Last year, Spectrum faced off with a shareholder that took issue with strategy, stock performance and executive pay.
